We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Third Survey of Prescription Pattern of Psychotropic Drugs in China

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2012 by Si Tianmei, Peking University.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01668810
First Posted: August 20, 2012
Last Update Posted: August 20, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Xian-Janssen Pharmaceutical Ltd.
Information provided by (Responsible Party):
Si Tianmei, Peking University
August 16, 2012
August 20, 2012
August 20, 2012
July 2012
September 2012   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
The Third Survey of Prescription Pattern of Psychotropic Drugs in China
The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder
The investigators aimed to examine the psychotropic prescription pattern in China.
Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
schizophrenia, depression and bipolar disorder patients
Prescription
Not Provided
  • Beijing region
    include six hospitals
  • Guangdong Province
    include 3 hospitals
  • Jiangsu province
    include 3 hospitals
  • Hebei province
    include 6 hospitals
  • Hubei Province
    include 7 hospitals
  • Shanxi province
    include 3 hospitals
  • Jiangxi province
    include 3 hospitals
  • Jilin province
    include 6 hospitals
  • Sichuan province
    include 3 hospitals
  • Shaanxi province
    include 3 hospitals
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
7000
July 2013
September 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria: aged 18-65, inpatient or outpatient, Patient must be willing and able to give written informed consent,the patient suffers from schizophrenia or depression or bipolar disorder -

Exclusion Criteria:aged<18or aged>65

Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT01668810
RISSCH4255
Yes
Not Provided
Not Provided
Si Tianmei, Peking University
Peking University
Xian-Janssen Pharmaceutical Ltd.
Study Chair: Xin Yu, MD. Peking University
Peking University
July 2012